Premium
Selective serotonin reuptake inhibitors and risk of major congenital anomalies for pregnancies in Japan: A nationwide birth cohort study of the Japan Environment and Children's Study
Author(s) -
Nishigori Hidekazu,
Obara Taku,
Nishigori Toshie,
Mizuno Satoshi,
Metoki Hirohito,
Hoshiai Tetsuro,
Watanabe Zen,
Sakurai Kasumi,
Ishikuro Mami,
Tatsuta Nozomi,
Nishijima Ichiko,
Fujiwara Ikuma,
Kuriyama Shinichi,
Arima Takahiro,
Nakai Kunihiko,
Yaegashi Nobuo
Publication year - 2017
Publication title -
congenital anomalies
Language(s) - English
Resource type - Journals
eISSN - 1741-4520
pISSN - 0914-3505
DOI - 10.1111/cga.12202
Subject(s) - medicine , odds ratio , cohort , obstetrics , pregnancy , incidence (geometry) , cohort study , genitourinary system , pediatrics , offspring , biology , physics , optics , genetics
We analyzed data from the Japan Environment and Children's Study (JECS), on the association between selective serotonin reuptake inhibitors (SSRI) use during pregnancy and the risk of developing of major congenital anomalies in Japan. JECS is an ongoing nationwide birth cohort study. The study includes 95 994 single pregnant women and their offspring. Among them, 172 used any SSRI up to the 12 th gestational week. Crude analyses show a significantly increased incidence of upper limb, abdominal, and urogenital abnormalities. In particular, the incidence of microcephaly, hydrencephalus, esophageal atresia, small intestinal atresia, and achondroplasia was significantly higher with than without exposure to these substances. On multivariate analyses, urogenital abnormality was significant (odds ratio 3.227; 95% confidence interval: 1.460–7.134). This Japanese nationwide birth cohort survey clarified that the use of any SSRI until the 12 th gestational week was associated with urogenital abnormality in children. The survey for association with minor classification abnormality needs further examination in Japan.